Department of Dermatology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Clin Exp Dermatol. 2022 Nov;47(11):2043-2045. doi: 10.1111/ced.15353. Epub 2022 Aug 30.
Pityriasis rubra pilaris (PRP) is a rare, scaly, keratotic inflammatory skin disease characterized by red scaly patches, keratosis papules, palmoplantar keratoderma and scaling of the scalp. In severe cases, ectropion of the eyelid may occur, and erythroderma may further develop. Recently, it has been reported that secukinumab, a monoclonal anti-interleukin-17A antibody, has certain efficacy in the treatment of PRP. Herein, we report a 3-year-old Chinese boy with severe Type III (classic juvenile) PRP who was successfully treated with secukinumab alone.
红糠疹(PRP)是一种罕见的、鳞屑状的、角化性炎症性皮肤病,其特征为红色鳞屑斑块、角化丘疹、掌跖角化病和头皮鳞屑。在严重的情况下,可能会发生眼睑外翻,并且可能进一步发展为红皮病。最近有报道称,单克隆抗白细胞介素-17A 抗体司库奇尤单抗在治疗 PRP 方面具有一定疗效。在此,我们报告了一例 3 岁中国男孩患有严重的 III 型(经典幼年型)PRP,单独使用司库奇尤单抗治疗后获得成功。